title: Skin conditions: emerging drug-resistant skin infections and infestations.
abstract: Methicillin-resistant Staphylococcus aureus (MRSA) skin infections are increasingly common. Automated microbiology systems are now available to detect MRSA and to determine antibiotic resistance patterns. Abscesses should be drained and antibiotics administered, with systemic antibiotics used to manage more severe infections. Until sensitivities are known and depending on local resistance rates, clindamycin is an option for empiric management of stable patients without bacteremia. For patients who are more ill, linezolid and vancomycin are alternatives, the latter being first-line treatment for children hospitalized with MRSA skin infections. Drug resistance also occurs in head lice management. Although topical permethrin is still the first-line drug management, its effectiveness has decreased due to permethrin-resistant strains. Patients who do not benefit from 2 applications of permethrin can be treated with topical malathion or topical ivermectin. Though not approved by the Food and Drug Administration (FDA) for treating head lice, oral ivermectin is sometimes used for difficult-to-treat cases. Permethrin is also the first-line management for scabies, though there is a concern that permethrin-resistant scabies may soon occur. For patients with scabies who do not benefit from topical treatment, oral ivermectin is recommended by the Centers for Disease Control and Prevention, although it is not approved by the FDA for this purpose.
authors.affiliation: San Joaquin General Hospital, French Camp, CA 95231, USA. rzuniga@sjgh.org
authors.forename: Ramiro
authors.initials: R
authors.lastname: Zuniga
authors.forename: Tam
authors.initials: T
authors.lastname: Nguyen
mesh_terms: D000284:Administration, Oral; D000287:Administration, Topical; D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D007306:Insecticides / Q000627:therapeutic use*; D008297:Male; D016106:Methicillin Resistance / Q000187:drug effects; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D017192:Skin Diseases, Bacterial / Q000188:drug therapy*; D012876:Skin Diseases, Parasitic / Q000188:drug therapy*; D018461:Soft Tissue Infections / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy*
chemical_list: D000890:Anti-Infective Agents; D007306:Insecticides